Lyme Disease Treatment Market Size to Worth Around USD 3 Bn by 2030

The global Lyme Disease Treatment market is expected to grow at a CAGR of around 1.6 % over the forecast period 2021 to 2030 and expected to reach the market value of around US$ 3 billion by 2030. 

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38527

Lyme disease is the most common vector-borne disease. Climate is one of the many important factors that influences the transmission, distribution, and incidence of Lyme disease. Additionally, climate change leads to rise in the survival and activity period of ticks, and increases in the potential risk of Lyme disease. Other factors that affect the number of Lyme disease cases are changes in the population of host species (particularly deer), which affect tick population size.

The incidence of Lyme disease in the U.S. has nearly doubled since 1991, from 3.74 reported cases per 100,000 people to 7.95 reported cases per 100,000 in 2014. According to the Centers for Disease Control and Prevention, 20,000 to 30,000 confirmed cases of Lyme disease have been reported in the U.S. per year. Lyme disease is most common in New Hampshire, Maine, and Vermont, which have experienced the largest increase in reported case rates since 1991.

According to the World Health Organization, the number of cases in Europe has increased steadily; more than 360,000 cases having been reported over the past two decades. According to the Westgate Pet Clinic, 5% to 15% canines are infected by Lyme disease. Hence, rise in prevalence of Lyme disease in both animals and humans is anticipated to boost the growth of the global market.

Report Scope

In terms of test type, the global Lyme disease treatment market has been bifurcated into medication and tick removal. The medication segment is expected to dominate the global Lyme disease treatment market from 2021 to 2030. A range of FDA-approved medications such as antibiotics and NSAIDs are available to treat the early stage Lyme disease. This drives the segment. The antibiotics sub-segment is projected to lead the medication segment during the forecast period. Patients with Lyme disease usually recover rapidly and completely with appropriate antibiotics in the early stages. This contributes to the growth of the sub-segment.  Cephalosporin, tetracycline, and macrolides antibiotics are commonly prescribed for the treatment of Lyme disease.

Based on route of administration, the global Lyme disease treatment market has been divided into oral, injectable, and topical. The oral segment is likely to grow at a higher CAGR from 2021 to 2031. The availability of products administered through oral route is projected to drive the segment. Physicians recommend doxycycline as the preferred agent for oral treatment of Lyme disease, due to its activity against other tick-borne illnesses.

In terms of distribution channel, the global Lyme disease treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to lead the global Lyme disease treatment market during the forecast period. The preference for distribution through retail pharmacy is anticipated to propel the segment.

Based on Region, North America is expected to account for a significant share of the global Lyme disease treatment market during the forecast period. The growth of the Lyme disease treatment market in the region can be attributed to rise in access to healthcare and increase in incidence of Lyme disease.

The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2030. The emergence of vector borne diseases in the region is projected to boost the growth of the market in the region. An article published in the National Library of Medicine stated that the prevalence rate of Lyme disease in northeast China was 1% to 4%. Moreover, rise in awareness about emerging tick-borne pathogens is anticipated to fuel the growth of the global market over the next few years.

Key Players

The report provides profiles of leading players operating in the global Lyme disease treatment market. These include GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Almirall, LLC, Mayne Pharma, Boehringer Ingelheim International GmbH, Galderma Laboratories, L.P., Lupin Pharmaceuticals, Inc., Chartwell Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Orion Corporation, and Amneal Pharmaceuticals LLC.

Global Lyme Disease Treatment Market: Segmentation

Market By Treatment Type

  • Medication
      • Antibiotics
        • Cephalosporin
        • Tetracycline
        • Macrolides
        • Others
      • NSAID
      • Others
  • Tick Removal

Market By Type of Bacteria

    • Borrelia burgdorferi
    • Borrelia mayonii
    • Borrelia afzelii
    • Borrelia garinii
    • Others

Market By Route of Administration

    • Oral
    • Injectable
    • Topic

Market By Application

    • Humans
    • Animals

Market By Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Market By Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of the Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38527

Research Methodology

The research methodology adopted by analysts for compiling the global lyme disease treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global lyme disease treatment market.

Table of Contents

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Lyme Disease Treatment Market, By Treatment Type

7.1.  Lyme Disease Treatment Market, by Treatment Type, 2021-2030

7.1.1.     Medication

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Tick Removal

7.1.2.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Lyme Disease Treatment Market, By Type of Bacteria

8.1.  Lyme Disease Treatment Market, by Type of Bacteria, 2021-2030

8.1.1.     Borrelia burgdorferi

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Borrelia mayonii

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Borrelia afzelii

8.1.3.1.          Market Revenue and Forecast (2016-2030)

8.1.4.     Borrelia garinii

8.1.4.1.          Market Revenue and Forecast (2016-2030)

8.1.5.     Others

8.1.5.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Lyme Disease Treatment Market, By Route of Administration

9.1.  Lyme Disease Treatment Market, by Route of Administration, 2021-2030

9.1.1.     Oral

9.1.1.1.          Market Revenue and Forecast (2016-2030)

9.1.2.     Injectable

9.1.2.1.          Market Revenue and Forecast (2016-2030)

9.1.3.     Topic

9.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 10.Global Lyme Disease Treatment Market, By Application

10.1.          Lyme Disease Treatment Market, by Application, 2021-2030

10.1.1.  Humans

10.1.1.1.       Market Revenue and Forecast (2016-2030)

10.1.2.  Animals

10.1.2.1.       Market Revenue and Forecast (2016-2030)

Chapter 11.Global Lyme Disease Treatment Market, By Distribution Channel

11.1.          Lyme Disease Treatment Market, by Distribution Channel, 2021-2030

11.1.1.  Hospital Pharmacies

11.1.1.1.       Market Revenue and Forecast (2016-2030)

11.1.2.  Retail Pharmacies

11.1.2.1.       Market Revenue and Forecast (2016-2030)

11.1.3.  Online Pharmacies

11.1.3.1.       Market Revenue and Forecast (2016-2030)

Chapter 12.Global Lyme Disease Treatment  Market, Regional Estimates and Trend Forecast

12.1.          North America

12.1.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.4.  Market Revenue and Forecast, by Application (2016-2030)

12.1.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.1.6.  U.S.

12.1.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.1.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.1.7.  Rest of North America

12.1.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.1.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.          Europe

12.2.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.4.  Market Revenue and Forecast, by Application (2016-2030)

12.2.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.6.  UK

12.2.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.7.  Germany

12.2.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.8.  France

12.2.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.9.  Rest of Europe

12.2.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.          APAC

12.3.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.4.  Market Revenue and Forecast, by Application (2016-2030)

12.3.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.6.  India

12.3.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.7.  China

12.3.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.8.  Japan

12.3.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.9.  Rest of APAC

12.3.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.          MEA

12.4.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.4.  Market Revenue and Forecast, by Application (2016-2030)

12.4.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.6.  GCC

12.4.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.7.  North Africa

12.4.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.8.  South Africa

12.4.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.9.  Rest of MEA

12.4.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.          Latin America

12.5.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.4.  Market Revenue and Forecast, by Application (2016-2030)

12.5.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.6.  Brazil

12.5.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.5.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.7.  Rest of LATAM

12.5.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.5.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

Chapter 13.   Company Profiles

13.1.                 GlaxoSmithKline plc

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.                 Pfizer, Inc.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.                 Novartis AG

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.                 F. Hoffmann-La Roche Ltd.

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.                 Almirall

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.                 LLC

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.                 Mayne Pharma

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.                 Boehringer Ingelheim International GmbH

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.                 Galderma Laboratories

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.              L.P.

13.10.1.                   Company Overview

13.10.2.                   Product Offerings

13.10.3.                   Financial Performance

13.10.4.                   Recent Initiatives

Chapter 14.   Research Methodology

14.1.                 Primary Research

14.2.                 Secondary Research

14.3.                 Assumptions

Chapter 15.   Appendix

15.1.                 About Us

15.2.                 Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38527

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com